The results showed that the durable efficacy sustained a similar improvement in their glucose control compared to those receiving treatment for 30 weeks. The results also showed that patients who switched from a BYETTA injection after 30 weeks to exenatide once weekly also experienced additional improvements in A1C and fasting plasma glucose.

Byetta has been on the market since 2005 and exenatide is not yet approved.

If you have watched Amylin over the last few days, it has been a tough patch for the stock as the diabetes competitor Novo-Nordisk AS (NYSE: NVO) results were far better than Wall Street was expecting.  On Friday, shares were north of $32.00 and they closed down at $26.84 yesterday.

While there has been relatively thin volume with under 30,000 shares with 1 hour and 10 minutes to the open, shares are up marginally in pre-market trading but are also already off the highs.  Unfortunately with an over an hour and a low-grade reaction to what seems like good news it is hard to see any major reaction so far.

Jon Ogg
June 10, 2008